FR2804959B1 - Utilisation de derives de paullones pour la fabrication de medicaments - Google Patents

Utilisation de derives de paullones pour la fabrication de medicaments

Info

Publication number
FR2804959B1
FR2804959B1 FR0001862A FR0001862A FR2804959B1 FR 2804959 B1 FR2804959 B1 FR 2804959B1 FR 0001862 A FR0001862 A FR 0001862A FR 0001862 A FR0001862 A FR 0001862A FR 2804959 B1 FR2804959 B1 FR 2804959B1
Authority
FR
France
Prior art keywords
paullon
medicaments
derivatives
manufacture
paullon derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0001862A
Other languages
English (en)
Other versions
FR2804959A1 (fr
Inventor
Laurent Meijer
Conrad Kunick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0001862A priority Critical patent/FR2804959B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU2001235691A priority patent/AU2001235691A1/en
Priority to CA002397560A priority patent/CA2397560A1/fr
Priority to PCT/FR2001/000455 priority patent/WO2001060374A1/fr
Priority to EP01907815A priority patent/EP1255551A1/fr
Priority to US10/203,977 priority patent/US7232814B2/en
Priority to JP2001559470A priority patent/JP2003522793A/ja
Publication of FR2804959A1 publication Critical patent/FR2804959A1/fr
Application granted granted Critical
Publication of FR2804959B1 publication Critical patent/FR2804959B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
FR0001862A 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments Expired - Fee Related FR2804959B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0001862A FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
CA002397560A CA2397560A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
PCT/FR2001/000455 WO2001060374A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
EP01907815A EP1255551A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
AU2001235691A AU2001235691A1 (en) 2000-02-15 2001-02-15 Use of paullone derivatives for making medicines
US10/203,977 US7232814B2 (en) 2000-02-15 2001-02-15 Use of paullone derivatives for making medicines
JP2001559470A JP2003522793A (ja) 2000-02-15 2001-02-15 製薬におけるパウロン誘導体の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001862A FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Publications (2)

Publication Number Publication Date
FR2804959A1 FR2804959A1 (fr) 2001-08-17
FR2804959B1 true FR2804959B1 (fr) 2006-04-28

Family

ID=8847019

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0001862A Expired - Fee Related FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Country Status (7)

Country Link
US (1) US7232814B2 (fr)
EP (1) EP1255551A1 (fr)
JP (1) JP2003522793A (fr)
AU (1) AU2001235691A1 (fr)
CA (1) CA2397560A1 (fr)
FR (1) FR2804959B1 (fr)
WO (1) WO2001060374A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
AU2002213132A1 (en) * 2000-10-10 2002-04-22 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
DE60206946T2 (de) 2001-09-21 2006-07-27 Sanofi-Aventis Substituierte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)onderivate gegen neurodegenerative erkrankungen
EP1295884A1 (fr) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Dérivés de 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one
JP4527404B2 (ja) * 2002-04-04 2010-08-18 エンゾン，インコーポレーテッド インドールのポリマー性アシル誘導体
EP1616568A3 (fr) * 2002-04-30 2006-06-21 Alcon, Inc Inhibiteurs de GSK-3 et de CDK comme agents antiglaucome
US7351407B2 (en) 2002-04-30 2008-04-01 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
DE10260618B4 (de) * 2002-12-23 2005-06-09 Faustus Forschungs Cie. Translational Cancer Research Gmbh Tumorhemmende annellierte Azepinonderivate
EP1615658A1 (fr) 2003-03-25 2006-01-18 The Board Of Trustees Of The University Of Illinois Procede d'inhibition de proliferation de cellules tumorales
UA87313C2 (ru) * 2004-05-12 2009-07-10 Байер Кропсайенс Аг Применение производного конденсированного азепинона для регулирования роста растений, композиция на его основе и способ регулирования роста растений
WO2006006939A1 (fr) * 2004-07-09 2006-01-19 Agency For Science, Technology And Research Modulation de gsk-3$g(b) et procede de traitement des maladies proliferatives
EP1791949A2 (fr) * 2004-09-02 2007-06-06 Neuro Therapeutics AB Methodes et materiaux concernant une production accrue de neurones a dopamine
EP1799684B1 (fr) * 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Composés à base de lactame utiles en tant qu'inhibiteurs de la protéine kinase
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20080207594A1 (en) * 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
ATE542535T1 (de) * 2005-05-04 2012-02-15 Develogen Ag Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
US7994160B2 (en) 2005-07-12 2011-08-09 Abbott Gmbh & Co. Kg Pyridazine compounds as glycogen synthase kinase 3 inhibitors
EP1757607A1 (fr) 2005-08-24 2007-02-28 Molisa GmbH Benzo¬2,3|azepino¬4,5-b|indol-6-ones N5-substitués pour le traitement des maladies tropiques
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
EP2068872A1 (fr) 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2009010298A2 (fr) * 2007-07-18 2009-01-22 Technische Universität Carolo-Wilhelmina Zu Braunschweig Dérivés de paullone et leurs utilisation
EP2198011B1 (fr) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Stimulation de la voie wnt dans la reprogrammation de cellules somatiques
US20120010178A1 (en) * 2008-10-21 2012-01-12 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
TW201026703A (en) * 2008-12-05 2010-07-16 Millennium Pharm Inc Thiolactams and uses thereof
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
WO2010124290A2 (fr) * 2009-04-24 2010-10-28 Whitehead Institute For Biomedical Research Compositions et procédés pour dériver ou cultiver des cellules pluripotentes
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
WO2016201581A1 (fr) 2015-06-18 2016-12-22 The Hospital For Sick Children Procédé de traitement de médulloblastome
CN112933094B (zh) 2015-06-18 2024-07-26 听治疗有限责任公司 预防和治疗听力损失的方法和组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AU778735B2 (en) * 1998-06-16 2004-12-16 Centre National De La Recherche Scientifique Fused azepinone cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
FR2804959A1 (fr) 2001-08-17
WO2001060374A1 (fr) 2001-08-23
AU2001235691A1 (en) 2001-08-27
US20030181439A1 (en) 2003-09-25
US7232814B2 (en) 2007-06-19
EP1255551A1 (fr) 2002-11-13
JP2003522793A (ja) 2003-07-29
CA2397560A1 (fr) 2001-08-23

Similar Documents

Publication Publication Date Title
NO2020040I1 (no) eltrombopag olamine - Forlenget SPC
EE200300497A (et) Pürasoolderivaadid HIV raviks
PT1175408E (pt) Derivados sulfonamida
DE60024115D1 (de) Pharmazeutisch wirksamer sulfonamid derivaten
ATE306928T1 (de) Fulvestrant formulierung
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
EE05020B1 (et) Glburiidi ravimkoostis
NO20031229L (no) Fremgangsmåte for fremstilling av börstevarer
ATE459598T1 (de) Sulfonamidderivate
DE60212604D1 (de) Tamponpackung
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
DE10083002T1 (de) Seifenverpackung
NO20024887D0 (no) Fremgangsmåte for fremstilling av benzokondenserte heterosykliske forbindelser
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
FR2821270B1 (fr) Utilisation de nicotine libre pour la fabrication d'une composition anti-cellulitique
NO20023702D0 (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
FR2791245B3 (fr) Baignoire pour bebes
DK1183236T3 (da) Cinnamoylaminoalkylsubstituerede benzensulfonamidderivater
EP1157700A4 (fr) Agent anti-vih
FR2791246B3 (fr) Baignoire pour bebes
NO20025385L (no) Fremgangsmate for fremstilling av sulfonylbenzoylguanidiniumsalter
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
FR2807922B3 (fr) Embout d'embossage pour la fabrication de saucisse
ATA12192000A (de) Antimykotisch wirkendes arzneimittel
FR2794001B1 (fr) La cravate suspensoir

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20111102